Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells

  • Authors:
    • Yoshiyuki Yamaguchi
    • Akiko Ohshita
    • Katsuji Hironaka
    • Riki Okita
    • Makoto Okawaki
    • Kazuo Matsuura
    • Ichiro Nagamine
    • Takuhiro Ikeda
    • Masahiro Ohara
    • Jun Hihara
  • View Affiliations

  • Published online on: July 1, 2006     https://doi.org/10.3892/or.16.1.165
  • Pages: 165-169
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A 29-year-old female breast cancer patient with multiple bone metastases (HLA-A2) was treated with adoptive transfer using autologous peripheral blood mononuclear cells (PBMCs) activated with the HLA-A2-matched allogeneic GC022588 gastric cancer cell line and interleukin-2 plus an immobilized anti-CD3 antibody culture system. The relief of bone pain in parallel with a decrease of serum carcinoembryonic antigen levels was obtained just after the administration of GC022588-activated effector lymphocytes, and a good quality of life was accomplished for 4 months. The GC022588-activated effector lymphocytes included 44% CD4+, 77% CD8+, and 26% CD4+CD8+ phenotypes, and expressed 25% killing activity against GC022588 stimulator cells at an E/T ratio of 50:1. T cell receptor (TCR) usage analysis for the effector cells showed oligoclonal expression of TCRVβ1, 3, 9, and 11, especially TCRVβ5.2, 12, 13.1 and 17, and their killing activity was significantly inhibited in the presence of anti-TCRαβ antibody and anti-TCRVβ12 antibody. SSCP analysis revealed clonotypic bands of TCRVβ12. These results suggest that shared antigens exist between breast and gastric adenocarcinomas. Allogeneic tumor cells can stimulate PBMCs to generate effector cells with selected TCRCDR3 usages that recognize tumor antigens. These effector lymphocytes may be good candidates for the adoptive immunotherapy of cancer.

Related Articles

Journal Cover

July 2006
Volume 16 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi Y, Ohshita A, Hironaka K, Okita R, Okawaki M, Matsuura K, Nagamine I, Ikeda T, Ohara M, Hihara J, Hihara J, et al: Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells. Oncol Rep 16: 165-169, 2006
APA
Yamaguchi, Y., Ohshita, A., Hironaka, K., Okita, R., Okawaki, M., Matsuura, K. ... Hihara, J. (2006). Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells. Oncology Reports, 16, 165-169. https://doi.org/10.3892/or.16.1.165
MLA
Yamaguchi, Y., Ohshita, A., Hironaka, K., Okita, R., Okawaki, M., Matsuura, K., Nagamine, I., Ikeda, T., Ohara, M., Hihara, J."Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells". Oncology Reports 16.1 (2006): 165-169.
Chicago
Yamaguchi, Y., Ohshita, A., Hironaka, K., Okita, R., Okawaki, M., Matsuura, K., Nagamine, I., Ikeda, T., Ohara, M., Hihara, J."Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells". Oncology Reports 16, no. 1 (2006): 165-169. https://doi.org/10.3892/or.16.1.165